Stock Events

Nippon Shinyaku. 

$8.15
1
+$0+0% Tuesday 15:00

Statistics

Day High
8.19
Day Low
8.19
52W High
12.14
52W Low
8.19
Volume
324
Avg. Volume
75
Mkt Cap
2.23B
P/E Ratio
0
Dividend Yield
2.49%
Dividend
0.2

Upcoming

Dividends

2.49%Dividend Yield
10Y Growth
N/A
5Y Growth
0.96%
3Y Growth
-3.33%
1Y Growth
106.09%

Earnings

9NovConfirmed
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
6.5
65.41
124.33
183.24
Expected EPS
82.32
Actual EPS
103.53

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NPPNY. It's not an investment recommendation.

About

Pharmaceuticals: Other
Health Technology
Manufacturing
Pharmaceutical Preparation Manufacturing
Nippon Shinyaku Co., Ltd. manufactures and sells pharmaceuticals and foodstuffs in Japan, Switzerland, and internationally. The company operates through Pharmaceuticals and Functional Food segments. It offers drugs for urological diseases, inflammation and allergies, hematologic malignancies, cardiovascular and metabolic diseases, gastrointestinal disorders, and other diseases. The company's products include Zalutia for urinary disorder caused by benign prostatic; Eviprostat for prostatic hypertrophy; Bladderon for pollakisuria; Estracyt for prostate cancer; Cialis for erectile dysfunction; Vidaza for myelodysplastic syndrome; Cylocide for solid tumor and acute leukemia; CylocideN for relapsed and refractory acute leukemia and malignant lymphoma; Gazyva for humanized anti-CD20 monoclonal antibody; Defiterio sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku Co., Ltd.'s products also comprise Uptravi, Adcirca, and Opsumit for pulmonary arterial hypertension; VILTEPSO for muscular dystrophy; Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler solution for allergic rhinitis; Azunol Gargle liquid, a gargling solution containing azulene; Isobide for oral osmotic diuresis/meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect for maintaining alcohol abstinence; and Onetram and Tramal for cancer and chronic pain. In addition, it researches, develops, and markets drugs in the areas of gynecology, otorhinolaryngology, and orthopedics. Further, the company provides functional foods, such as health food ingredients, preservatives, protein preparations, supplements, and spice and condiments. Nippon Shinyaku Co., Ltd. was founded in 1911 and is headquartered in Kyoto, Japan.
Show more...
CEO
Employees
2186
Country
US
ISIN
US65461U1088

Listings